“Excellent staff and doctors, professionalism paramount. Treatment detailed, very effective. I chose them for a second opinion and they should have been first.”
Ozurdex Intravitreal Implant for Retinal Conditions
The Ozurdex Procedure
The implant is placed in the eye during a quick in-office procedure. Most patients tolerate it well, and the process is straightforward from start to finish.
Before the implant is placed, your Retina Specialist will apply numbing drops to your eye. The eye surface is then cleaned with an antiseptic solution to reduce the risk of infection. Some patients receive additional numbing medication around the eye as needed. Your Retina Specialist will walk you through every step and answer any questions before proceeding.
The Ozurdex implant is delivered using a specially designed single-use applicator with a fine needle. The needle passes through the white part of the eye (the sclera) into the vitreous, which is the clear gel that fills the inside of the eye, and the implant is released. The placement itself takes only a few seconds. Most patients feel brief pressure rather than sharp pain. The full appointment, including preparation and post-procedure monitoring, typically lasts around 30 to 60 minutes.
It is normal to experience mild discomfort, a gritty sensation, or slightly blurred vision for the remainder of the day. These effects typically resolve within a few hours. Your Retina Specialist may check your eye pressure before you leave the office. You can return to most normal activities the same day, but you should avoid rubbing your eye, swimming, and dusty environments for a few days to support healing.
Treatment Schedule and Monitoring
Because Ozurdex provides sustained medication delivery over several months, treatments are spaced further apart than many standard injections. Regular monitoring between treatments is an important part of keeping the condition under control safely.
Ozurdex releases medication over approximately four to six months. Most patients receive a new implant roughly every four to six months, though your Retina Specialist will determine the right timing for you based on imaging results and how well your vision is responding. This longer interval between treatments can reduce the total number of office visits compared to monthly injection schedules.
Your Retina Specialist may recommend Ozurdex alongside other treatments depending on your condition. For diabetic macular edema, it is sometimes used in combination with anti-VEGF injections (medications such as Avastin, Lucentis, Eylea, or Vabysmo) when those agents alone have not fully resolved the swelling. For noninfectious uveitis, Ozurdex may be part of a broader inflammation management plan. The treatment approach is always tailored to your specific diagnosis and history.
At each follow-up visit, your Retina Specialist will use optical coherence tomography (OCT), an imaging test that measures retinal thickness in detail, to track changes in macular swelling. Visual acuity testing at every visit helps gauge whether your vision is improving or holding steady. Eye pressure is also measured regularly because corticosteroids can raise pressure inside the eye in some patients. Consistent monitoring allows your care team to catch and address any concerns early.
Benefits and Risks
Like all medical treatments, Ozurdex carries both potential benefits and risks. Your Retina Specialist will review these with you in detail so that you can make an informed decision about your care.
Ozurdex can reduce macular edema and improve vision in patients with DME, RVO-related macular edema, and noninfectious posterior uveitis. Its sustained-release design means fewer injection visits compared to monthly treatments. Because the implant dissolves on its own, no removal procedure is required. For patients with a significant inflammatory component to their condition, or for those who have not responded fully to anti-VEGF therapy alone, Ozurdex offers an important treatment option.
Corticosteroids can raise intraocular pressure (the pressure inside the eye) in some patients. In clinical trials, a meaningful portion of patients who received Ozurdex experienced elevated pressure, with the increase typically peaking around eight weeks after the implant is placed. Most cases can be managed effectively with pressure-lowering eye drops. Your Retina Specialist will monitor your eye pressure closely at every visit. Patients with a history of glaucoma or a prior steroid-related pressure response require especially careful monitoring.
Repeated exposure to corticosteroids can accelerate cataract formation (clouding of the natural lens inside the eye). This risk applies mainly to patients who still have their natural lens. Patients who have already had cataract surgery and have an artificial lens in place do not face this risk. If a cataract develops and affects your vision, it can be treated with standard cataract surgery. Your Retina Specialist will weigh the benefits of continued treatment against this risk for your individual situation.
Rare but serious risks include infection inside the eye (endophthalmitis), retinal detachment, bleeding inside the eye (vitreous hemorrhage), and movement of the implant into an unintended position. These complications are uncommon, but they require immediate attention.
- Sudden vision loss
- Severe or worsening eye pain
- A significant increase in floaters or flashes of light
- New distortion in your central vision
If you experience any of these symptoms after the procedure, contact your Retina Specialist right away or go to the nearest emergency room.
Comparing Ozurdex to Other Treatment Options
Ozurdex is one of several treatment approaches available for macular edema and intraocular inflammation. Understanding how it compares to other options can help you have a more informed conversation with your Retina Specialist.
Anti-VEGF medications, including Avastin (bevacizumab), Lucentis (ranibizumab), Eylea (aflibercept), and Vabysmo (faricimab), are typically the first-line treatment for diabetic macular edema and RVO-related macular edema. These agents are injected more frequently, often monthly or every one to two months. Ozurdex provides a longer duration of action per treatment but carries risks of elevated eye pressure and cataract progression that anti-VEGF agents generally do not. Your Retina Specialist may recommend Ozurdex when anti-VEGF therapy has not provided sufficient improvement, when inflammation is a primary driver of the swelling, or when the longer interval between treatments is beneficial for your situation.
Iluvien (fluocinolone acetonide intravitreal implant) is another corticosteroid implant approved for chronic diabetic macular edema. Iluvien releases medication over approximately 36 months, which is considerably longer than Ozurdex. Unlike Ozurdex, Iluvien is not biodegradable and remains in the eye permanently. Ozurdex may be preferred for patients who need shorter-term corticosteroid treatment, who are being evaluated for how their condition responds to steroids before committing to longer therapy, or for whom the biodegradable design is more appropriate. Your Retina Specialist will recommend the option that best fits your diagnosis, treatment history, and risk profile.
Who May Benefit from Ozurdex
Not every patient with macular edema or uveitis is a candidate for Ozurdex. Your Retina Specialist will evaluate your full clinical picture before recommending this treatment.
Ozurdex is often considered for patients with diabetic macular edema, macular edema from retinal vein occlusion, or noninfectious posterior uveitis who have not responded well enough to anti-VEGF therapy, or whose condition has a strong inflammatory component. Patients who have already had cataract surgery are particularly well-suited because the risk of lens clouding is no longer a factor. Those who prefer or require less frequent treatment visits may also benefit from Ozurdex's longer dosing interval.
If you have diabetes, a history of retinal vein occlusion, or uveitis, it is important to watch for changes in your central vision. The following symptoms may indicate macular edema or active inflammation and should be evaluated promptly.
- Blurred or dim central vision
- Difficulty reading or seeing fine detail
- Straight lines that appear wavy or distorted
- A dark or missing area in your central vision
Regular monitoring visits allow your Retina Specialist to detect macular swelling and inflammation early, sometimes before you notice any changes in your vision.
Frequently Asked Questions
Here are answers to questions patients commonly ask about Ozurdex. These address practical decisions and situations not fully covered in the sections above.
Yes, we strongly recommend arranging a ride home after your Ozurdex appointment. The numbing drops used during the procedure can temporarily affect your comfort and clarity of vision, making it unsafe to drive immediately afterward. Planning ahead for transportation allows you to relax during recovery instead of worrying about getting home.
Improvement may not be immediate. Many patients begin to notice better vision within the first few weeks as macular swelling decreases, but the timeline varies depending on the severity of the underlying condition. Your Retina Specialist will use OCT imaging and vision testing at follow-up visits to objectively track your treatment response, even before you notice subjective changes in your sight.
Ozurdex can be repeated over time, but long-term use carries a cumulative risk of elevated eye pressure and, in patients with a natural lens, accelerated cataract progression. Your Retina Specialist will reassess the risks and benefits at each treatment cycle. In some cases, treatment may be adjusted, combined with other therapies, or replaced by a different approach as your condition evolves.
Elevated intraocular pressure after an Ozurdex implant is usually manageable with prescription pressure-lowering eye drops. Pressure increases tend to peak around eight weeks after placement and often improve as the implant's medication level gradually decreases. If drops are not sufficient to control the pressure, your Retina Specialist will discuss further options. This is one of the key reasons regular follow-up appointments after the procedure are essential.
Ozurdex can be used in patients with a history of glaucoma, but it requires more careful monitoring than in patients without that history. Corticosteroids can raise eye pressure, which is especially significant when the optic nerve (the nerve connecting the eye to the brain) is already under stress from glaucoma. Your Retina Specialist will coordinate closely with your glaucoma provider and check your pressure at every visit to keep it within a safe range.
The decision to use Ozurdex is not typically an emergency, but the conditions it treats can sometimes progress quickly. If you experience sudden vision loss, a significant increase in floaters, flashes of light, or a new dark area in your central vision at any time, whether before or after treatment, you should seek immediate care. These symptoms can indicate a retinal detachment or other urgent complication that requires prompt evaluation and treatment.
Schedule a Consultation at Atlantic Retina Center
Our team of fellowship-trained, ABO board-certified Retina Specialists at Atlantic Retina Center is dedicated exclusively to the care of the retina, vitreous, and macula. We serve patients across the Eastern Shore of Maryland and central and southern Delaware, offering expert evaluation and a full range of retinal treatments, including Ozurdex and other advanced options. If you have been diagnosed with macular edema or uveitis, or if you are noticing changes in your central vision, we encourage you to contact us to schedule a consultation. Getting the right diagnosis and the right treatment plan early makes a meaningful difference in protecting your sight.